Table 2 Hazard ratios for non-response to treatment

BMI (kg/m²)

43

26.31 (19.8-52.6)

 Tertile 1 (lowest)

14

23.6 (19.8-25.0)

1.0 (Reference)

 Tertile 2

14

26.3 (25.1-30.3)

3.9 (1.24-12.37)

0.02

 Tertile 3 (highest)

15

33.2 (30.4-52.6)

3.4 (1.04-11.01)

0.04

Duration of diabetes (years)

43

11 (0.1-38)

 Tertile 1 (lowest)

15

4 (0.1-6)

1.0 (Reference)

 Tertile 2

15

12 (8-17)

1.7 (0.67-4.4)

0.25

 Tertile 3 (highest)

13

23 (18-38)

1.7 (0.63-4.5)

0.30

CPR6 (ng/mL)

43

3.9 (0.5-11.0)

 Tertile 1 (lowest)

15

2.0 (0.5-2.7)

1.0 (Reference)

 Tertile 2

14

4.0 (2.8-4.9)

0.4 (0.13-1.01)

0.054

 Tertile 3 (highest)

14

6.7 (5.3-11.0)

1.3 (0.51-3.28)

0.59

U-CPR (μg/day)

43

71.6 (16.0-249.8)

 Tertile 1 (lowest)

15

33.7 (16.0-49.7)

1.0 (Reference)

 Tertile 2

14

73.7 (50.8-112.8)

0.4 (0.16-1.18)

0.10

 Tertile 3 (highest)

14

160.0 (121.7-249.8)

0.6 (0.23-1.34)

0.19

Average preprandial glucose level over 2 days after the initiation of GLP-1 receptor agonist treatment (mg/dL)

43

149.3 (99.8-246.2)

 Tertile 1 (lowest)

15

130.3 (99.8-137.7)

1.0 (Reference)

 Tertile 2

14

149.7 (140.2-161.0)

3.5 (1.19-10.12)

0.02

 Tertile 3 (highest)

14

188.7 (161.5-246.2)

3.1 (1.04-8.97)

0.04

Previous antidiabetic treatment

43

 Diet and/or metformin

11

1.0 (Reference)

 Sulfonylurea

14

5.0 (1.13-22.16)

0.03

 Insulin

18

5.3 (1.16-24.56)

0.03